Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

Non-alcoholic fatty liver disease (NAFLD) is a global public health concern. Its natural history, the development of non-alcoholic steatohepatitis (NASH) and fibrosis, is highly variable, prone to endogenous (e.g., genetics, microbiota) and exogenous (e.g., nutrition, alcohol, physical activity) disease modifiers, and can fluctuate over time. The complexity of its pathophysiology is reflected by the multitude of pharmacological targets in development. NASH clinical trials have provided valuable insight that is applicable to future trial design.

Source: Journal of Hepatology - July 8, 2019 Category: Gastroenterology Authors: Mary E. Rinella, Frank Tacke, Arun J. Sanyal, Quentin M. Anstee, the participants of the AASLD/EASL Workshop Tags: Review Source Type: research